How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

77,731 results for

Diabetes Mellitus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Full Text available with Trip Pro

Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Alpha-glucosidase inhibitors (AGI) reduce blood glucose levels and may thus prevent or delay type 2 diabetes mellitus (T2DM) and its associated complications in people at risk of developing of T2DM.To assess the effects of AGI in people with impaired glucose tolerance (IGT), impaired fasting blood glucose (IFG (...) model with assessment of risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the overall quality of the evidence by using the GRADE instrument.For this update of the Cochrane Review (first published 2006, Issue 4) we included 10 RCTs (11,814 participants), eight investigating acarbose and two investigating voglibose, that included people with IGT or people "at increased risk for diabetes

2018 Cochrane

2. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Full Text available with Trip Pro

Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues are able to prevent or delay

2017 Cochrane

3. Fetal biometry for guiding the medical management of women with gestational diabetes mellitus for improving maternal and perinatal health. (Abstract)

Fetal biometry for guiding the medical management of women with gestational diabetes mellitus for improving maternal and perinatal health. Gestational diabetes mellitus (GDM) is a common medical condition that complicates pregnancy and causes adverse maternal and fetal outcomes. At present, most treatment strategies focus on normalisation of maternal blood glucose values with use of diet, lifestyle modification, exercise, oral anti-hyperglycaemics and insulin. This has been shown to reduce (...) the incidence of adverse outcomes, such as birth trauma and macrosomia. However, this involves intensive monitoring and treatment of all women with GDM. We propose that using medical imaging to identify pregnancies displaying signs of being affected by GDM could help to target management, allowing low-risk women to be spared excessive intervention, and facilitating better resource allocation.We wanted to address the following question: in women with gestational diabetes, does the use of fetal imaging plus

2019 Cochrane

4. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Dapagliflozin/Saxagliptin bzw. Dapagliflozin/Metformin zur Behandlung des Diabetes mellitus Typ 2 [unpublished]. 2015. 11. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie: Therapieplanung bei Typ-2-Diabetes; Lagfassung; Version 4 [online]. 11.2014 [Accessed: 28.02.2018]. URL: http://www.leitlinien.de/mdb/downloads/nvl/diabetes-mellitus/dm- therapie-1aufl-vers4-lang.pdf. 12. Institut für Qualität (...) Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Dapagliflozin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

5. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dapagliflozin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 March 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports A17-66 Dapagliflozin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A17-66 Version 1.0 Dapagliflozin/metformin (type 2 diabetes mellitus) 28 March 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin/metformin (type 2 diabetes mellitus) – Benefit

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)

Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Sitagliptin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 19 December 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text (...) is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-65 Sitagliptin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-65 Version 1.0 Sitagliptin (type 2 diabetes mellitus) 19 December 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sitagliptin (type 2 diabetes mellitus

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Semaglutid (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 January 2019). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A18-75 Semaglutide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-75 Version 1.0 Semaglutide (type 2 diabetes mellitus) 30 January 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Semaglutide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

8. Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.8 of the dossier assessment Dapagliflozin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse) (Version 1.0; Status: 27 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A19-53 Dapagliflozin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A19-53 Version 1.0 Dapagliflozin (type 2 diabetes mellitus) 27 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin (type 2 diabetes mellitus) – Benefit assessment

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

9. Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53

Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53 1 Translation of addendum A19-92 Dapagliflozin (Diabetes mellitus Typ 2) – Addendum zum Auftrag A19-53 (Version 1.0; Status: 29 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 November 2019 1.0 Commission: A19-92 Version: Status: IQWiG Reports – Commission (...) No. A19-92 Dapagliflozin (type 2 diabetes mellitus) – Addendum to Commission A19-53 1 Addendum A19-92 Version 1.0 Dapagliflozin – Addendum to Commission A19-53 29 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dapagliflozin (type 2 diabetes mellitus) – Addendum to Commission A19-53 Commissioning agency Federal Joint Committee Commission awarded on 12 November 2019 Internal Commission

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

10. Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52

Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52 1 Translation of addendum A19-93 Dapagliflozin/Metformin (Diabetes mellitus Typ 2) – Addendum zum Auftrag A19-52 (Version 1.0; Status: 29 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 November 2019 1.0 Commission: A19-93 Version: Status: IQWiG Reports (...) – Commission No. A19-93 Dapagliflozin/metformin (type 2 diabetes mellitus) – Addendum to Commission A19-52 1 Addendum A19-93 Version 1.0 Dapagliflozin/metformin – Addendum to Commission A19-52 29 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Dapagliflozin/metformin (type 2 diabetes mellitus) – Addendum to Commission A19-52 Commissioning agency Federal Joint Committee Commission awarded

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dapagliflozin (Diabetes mellitus Typ 1) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission (...) No. A19-37 Dapagliflozin (type 1 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-37 Version 1.0 Dapagliflozin (type 1 diabetes mellitus) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin (type 1 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dapagliflozin/Metformin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche Erkenntnisse) (Version 1.0; Status: 27 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. A19-52 Dapagliflozin/metformin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 (new scientific findings) Extract of dossier assessment A19-52 Version 1.0 Dapagliflozin/metformin (type 2 diabetes mellitus) 27 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin/metformin (type

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37

Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37 1 Translation of addendum A19-79 Dapagliflozin (Diabetes Mellitus Typ 1) – Addendum zum Auftrag A19-37 (Version 1.0; Status: 27 September 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 27 September 2019 1.0 Commission: A19-79 Version: Status: IQWiG Reports – Commission (...) No. A19-79 Dapagliflozin (type 1 diabetes mellitus) – Addendum to Commission A19-37 1 Addendum A19-79 Version 1.0 Dapagliflozin – Addendum to Commission A19-37 27 September 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dapagliflozin (type 1 diabetes mellitus) – Addendum to Commission A19-37 Commissioning agency: Federal Joint Committee Commission awarded on: 9 September 2019 Internal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Linagliptin (Diabetes mellitus Typ 2) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 29 August 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A19-49 Empagliflozin/linagliptin (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-49 Version 1.0 Empagliflozin/linagliptin (type 2 diabetes mellitus) 29 August 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Empagliflozin/linagliptin (type 2 diabetes mellitus) – Benefit assessment according

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

15. Insulin degludec + liraglutide (Xultophy) - Diabetes mellitus, Type 2

Insulin degludec + liraglutide (Xultophy) - Diabetes mellitus, Type 2 insulin degludec + liraglutide | CADTH.ca Find the information you need insulin degludec + liraglutide insulin degludec + liraglutide Last Updated: October 3, 2019 Result type: Reports Project Number: SR0599-000 Product Line: Generic Name: insulin degludec + liraglutide Brand Name: Xultophy Manufacturer: Novo Nordisk Canada Inc. Indications: Diabetes mellitus, Type 2 Manufacturer Requested Reimbursement Criteria 1 (...) : To be reimbursed as an adjunct to lifestyle modifications to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medications combined with basal insulin, or basal insulin alone do not provide adequate glycemic control. Submission Type: New Combination Project Status: Active Biosimilar: No Fee Schedule: Schedule A The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH

2019 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

16. A1C Testing in the Diagnosis of Diabetes Mellitus

A1C Testing in the Diagnosis of Diabetes Mellitus A1C Testing in the Diagnosis of Diabetes Mellitus Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics A1C Testing in the Diagnosis of Diabetes Mellitus View/ Open Date 2006-07 Format Metadata Abstract A1C testing is highly specific compared with a two-hour oral glucose (...) tolerance test (OGTT) or a fasting plasma glucose test. However, because A1C testing is not sensitive enough to rule out diabetes if levels are normal, the test should not be used for diagnosing diabetes. (Strength of recommendation: C). URI Part of Citation American Family Physician, 74(1) 2006. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2019 Clinical Inquiries

17. Minimed 670g - for the management of type 1 diabetes mellitus

Minimed 670g - for the management of type 1 diabetes mellitus Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for the is located below. Updated: The following

2019 Health Canada - Drug and Health Product Register

18. A1C Testing in the Diagnosis of Diabetes Mellitus

A1C Testing in the Diagnosis of Diabetes Mellitus A1C Testing in the Diagnosis of Diabetes Mellitus Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics A1C Testing in the Diagnosis of Diabetes Mellitus View/ Open Date 2006-07 Format Metadata Abstract A1C testing is highly specific compared with a two-hour oral glucose (...) tolerance test (OGTT) or a fasting plasma glucose test. However, because A1C testing is not sensitive enough to rule out diabetes if levels are normal, the test should not be used for diagnosing diabetes. (Strength of recommendation: C). URI Part of Citation American Family Physician, 74(1) 2006. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2019 Clinical Inquiries

19. Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research (...) proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Type 2 Diabetes Mellitus Patient population. Adults Objectives. To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic

2020 University of Michigan Health System

20. HbA1c point of care test for the management of diabetes mellitus

HbA1c point of care test for the management of diabetes mellitus 1 Public Summary Document Application No. 1431.1 – HbA1c point of care test for the diagnosis and management of diabetes mellitus Applicant: HTAnalysts Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application for the resubmission of glycated haemoglobin (HbA1c) Point of Care (...) (PoC) testing for the management of patients with diabetes mellitus was received from HTAnalysts for IVD Australia by the Department of Health. 2. MSAC’s advice to the Minister MSAC indicated it was supportive of MBS listing of HbA1c PoC testing for the management and monitoring of established diabetes mellitus, including in pregnancy. Before making a final recommendation, MSAC advised that, to ensure good testing practice and cost-neutrality, the appropriate quality assurance standards

2019 Medical Services Advisory Committee

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>